Melanotan II is a non-selective melanocortin agonist with a development status of "never approved; research use only". The Institute rates the strength of its published evidence as limited. A non-selective melanocortin agonist that drives melanogenesis, with a well-documented adverse-effect profile and no approval anywhere.
The distinction that matters most when reading about Melanotan II is between what has been demonstrated and what has been proposed. Mechanistic plausibility is not evidence of effect, and a compound can have a well-characterised receptor interaction while producing no measurable clinical benefit. That gap is where most of the confusion in this space lives.
Where human data exists for Melanotan II, endpoints are frequently surrogate measures rather than outcomes people care about. A change in a biomarker is a reason to run a larger trial, not a reason to conclude the trial would succeed.
The Institute has independently tested 3 Melanotan II samples from 2 companies. 100% met their label claims on purity and content. Measured purity ranged from 97% to 97.6%, averaging 97.3%. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
